Frontotemporal dementia and pharmacologic interventions

Journal of Neuropsychiatry and Clinical Neurosciences

Volumn 22, Issue 1, 2010, Pages 19-29

  Kaye, Edward D ^a,b   Petrovic Poljak, Ana ^c,d   Verhoeff, Nicolaas P L G ^a,c,e   Freedman, Morris ^c,e,f  

^a Kunin Lunenfeld Applied Research Unit and Department of Food and Nutrition Services and Baycrest Centre for Geriatric Care   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c at Baycrest   (United States)

^d Brain Health Centre Clinics

^e UNIVERSITY OF TORONTO   (Canada)

^f ROTMAN RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; BENZODIAZEPINE; CHOLINE ACETYLTRANSFERASE; CHOLINESTERASE INHIBITOR; DONEPEZIL; FLUOXETINE; FLUVOXAMINE; GALANTAMINE; MEMANTINE; MONOAMINE OXIDASE INHIBITOR; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; NEUROTRANSMITTER; PAROXETINE; PIRACETAM; PLACEBO; PSYCHOSTIMULANT AGENT; RIVASTIGMINE; SELEGILINE; SEROTONIN 1 RECEPTOR; SEROTONIN 2 RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; UNINDEXED DRUG;

ALZHEIMER DISEASE; ARTICLE; ATAXIC APHASIA; CHOLINERGIC SYSTEM; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; COMPULSION; CONTROLLED CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE COURSE; DOPAMINERGIC SYSTEM; DRUG EFFICACY; DRUG TARGETING; DRUG TOLERABILITY; DYSPHAGIA; FRONTAL CORTEX; FRONTOTEMPORAL DEMENTIA; HUMAN; MENTAL DISEASE; MOTOR NEURON DISEASE; NEUROPROTECTION; NORADRENERGIC SYSTEM; PERSONALITY DISORDER; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; PYRAMIDAL NERVE CELL; RANDOMIZED CONTROLLED TRIAL; SEMANTIC DEMENTIA; SEROTONINERGIC SYSTEM;

EID: 76749121050     PISSN: 08950172     EISSN: None     Source Type: Journal    
DOI: 10.1176/jnp.2010.22.1.19     Document Type: Article

References (99)

1. Neary D, Snowden JS, Gustafson L, et al: Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998; 51:1546-1554
2. Hodges JR, Miller B: The classification, genetics, and neuropathology of frontotemporal dementia introduction to the special topic papers, part I. Neurocase 2001; 7:31-35
3. Gustafson L: Frontal lobe degeneration of non-Alzheimer type II: clinical picture and differential diagnosis. Arch Gerontol Geriatr 1987; 6:209-223
4. Weder ND, Aziz R, Wilkins K, et al: Frontotemporal dementias: a review. Ann Gen Psychiatry 2007; 6:15
5. Lough S, Kipps CM, Treise C, et al: Social reasoning, emotion, and empathy in frontotemporal dementia. Neuropsychologia 2006; 44:950-958
6. Rahman S, Sahakian BJ, Hodges JR, et al: Specific cognitive deficits in early frontal variant frontotemporal dementia. Brain 1999; 122:1469-1493
7. Ames D, Cumming JL, Wirshing WC, et al: Repetitive and compulsive behavior in frontal lobe degenerations. J Neuropsychiatry Clin Neurosci 1994; 6:100-113
8. Chow TW, Mendez MF: Goals in symptomatic pharmacologic management of frontotemporal lobar degeneration. Am J Alzheimers Dis Other Demen 2002; 17:267-272
9. Gregory CA, Hodges JR: Clinical features of frontal lobe dementia in comparison to Alzheimer's disease. J Neural Transm 1996; 47:103-123
10. Mendez MF, Perryman KM, Miller BL, et al: Compulsive behaviors as presenting symptoms of frontotemporal dementia. J Geriatr Psychiatry Neurol 1997; 10:154-157
11. Miller BL, Darby AL, Swartz JR, et al: Dietary changes, compulsions, and sexual behavior in frontotemporal degeneration. Dementia 1995; 6:195-199
12. Swartz JR, Miller BL, Lesser IM, et al: Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors. J Clin Psychiatry 1997; 58:212-216
13. Liu W, Miller BL, Kramer JH, et al: Behavioral disorders in the frontal and temporal variants of frontotemporal dementia. Neurology 2004; 62:742-748
14. Boxer AL, Boeve BF: Frontotemporal dementia treatment: current symptomatic therapies and implications of recent genetic, biochemical, and neuroimaging studies. Alzheimer Dis Assoc Disord 2007; 21:S79-S87
15. Walker AJ, Meares S, Sachdev PS, et al: The differentiation of mild frontotemporal dementia from Alzheimer's disease and healthy aging by neuropsychological tests. Int Psychogeriatr 2005; 17:57-68
16. Elderkin-Thompson V, Boone KB, Hwang S, et al: Neurocognitive profiles in elderly patients with frontotemporal degeneration or major depressive disorder. J Int Neuropsychol Soc 2004; 10:753-771
17. Graham A, Davies R, Xuereb J, et al: Pathologically proven frontotemporal dementia presenting with severe amnesia. Brain 2005; 128:597-605
18. Pasquier F, Grymonprez L, Lebert F, et al: Memory impairment differs in frontotemporal dementia and Alzheimer's disease. Neurocase 2001; 7:161-171
19. Glosser G, Gallo JL, Clark CM, et al: Memory encoding and retrieval in frontotemporal dementia and Alzheimer's disease. Neuropsychology 2002; 16:190-196
20. McMurtray AM, Chen AK, Shapira JS, et al: Variations in regional SPECT hypoperfusion and clinical features in frontotemporal dementia. Neurology 2006; 66:517-522
21. Kertesz A, McMonagle P, Blair M, et al: The evolution and pathology of frontotemporal dementia. Brain 2005; 128:1996-2005
22. Hansen LA, Deteresa R, Tobias H, et al: Neocortical morphometry and cholinergic neurochemistry in Pick's disease. Am J Pathol 1998; 131:507-518
23. Procter AW, Qurne M, Francis PT: Neurochemical features of frontotemporal dementia. Dement Geriatr Cogn Disord 1999; 10(suppl 1):80-84
24. Sparks DL, Markesberry WR: Altered serotonergic and cholinergic synaptic markers in Pick's disease. Arch Neurol 1991; 48:796-799
25. Meier-Ruge W, Iwangoff P, Reichlmeier K: Neurochemical enzyme changes in Alzheimer's and Pick's disease. Arch Gerontol Geriatr 1984; 3:161-165
26. Odawara T, Shiozaki K, Iseki E, et al: Alterations of muscarinic acetylcholine receptors in atypical Pick's disease without Pick bodies. J Neurol Sci 2003; 74:965-967
27. Weinberger DR, Gibson R, Coppola R, et al: The distribution of cerebral muscarinic acetylcholine receptors in vivo in patients with dementia: a controlled study with 123IQNB and single photon emission computed tomography. Arch Neurol 1991; 48:169-176
28. Tagliavini F, Pilleri G: Basal nucleus of Meynert: a neuropathological study in Alzheimer's disease, simple senile dementia, Pick's disease, and Huntington's chorea. J Neurol Sci 1983; 63:243-260
29. Uhl GR, Hilt DC, Hedreen JC, et al: Pick's disease (lobar sclerosis): depletion of neurons in the nucleus basalis of Meynert. Neurology 1983; 33:1470-1473
30. Franceschi M, Anchisi D, Pelati O, et al: Glucose metabolism and serotonin receptors in the frontotemporal lobe degeneration. Ann Neurol 2005; 57:216-225
31. Miller BL: Pick's Disease and Frontotemporal Dementias: Clinical and Biological Overview. Philadelphia, American Academy of Neurology, 2001
32. Yang Y, Schmitt HP: Frontotemporal dementia: evidence for impairment of ascending serotoninergic but not noradrenergic innervations: immunocytochemical and quantitative study using a graph method. Acta Neuropathol 2001; 101:256-270
33. Frisoni GB, Pizzolato G, Bianchetti A, et al: Single photon emission computed tomography with [99Tc]-HM-PAO and [123I]-IBZM in Alzheimer's disease and dementia of frontal type: preliminary results. Acta Neurol Scand 1994; 89:199-203
34. Rinne JO, Laine M, Kaasinen V, et al: Striatal dopamine transporter and extrapyramidal symptoms in frontotemporal dementia. Neurology 2002; 58:1489-1493
35. Sperfeld AD, Collatz MB, Baier H, et al: Ftdp-17: an earlyonset phenotype with parkinsonism and epileptic seizures caused by a novel mutation. Ann Neurol 1999; 46:708-715
36. Francis PT, Holmes C, Webster MT, et al: Preliminary neurochemical findings in non-Alzheimer dementia due to lobar atrophy. Dementia 1993; 4:172-177
37. Sjogren M, Wikkelso D, Ostling S, et al: Biological correlates of clinical subgroups of Alzheimer's disease. Dement Geriatr Cogn Disord 2002; 14:191-197
38. Luque JM, Chan-Palay V: Alterations in tyrosine hydroxylase immunoreactive neurons of the locus ceruleus in Pick's disease. Dementia 1991; 2:291-296
39. Ferrer I: Neurons and their dendrites in frontotemporal dementia. Dement Geriatr Cogn Disord 1999; 10(suppl 1):55-60
40. Mendez MF, Shapira JS: Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. Am J Geriatr Psychiatry 2007; 15:84-87
41. Moretti R, Torre P, Antonello RM, et al: Rivastigmine in frontotemporal dementia: an open-label study. Drugs Aging 2004; 21:931-937
42. Kertesz A, Morlog D, Light M, et al: Galantamine in frontotemporal dementia and primary progressive aphasia. Dement Geriatr Cogn Disord 2008; 25:178-185
43. Lampl Y, Sadeh M, Lorberboym M: Efficacy of acetylcholinesterase inhibitors in frontotemporal dementia. Ann Pharmacother 2004; 38:1967-1968
44. Chow TW: Treatment approaches to symptoms associated with frontotemporal degeneration. Curr Psychiatry Rep 2005; 7:376-380
45. Moretti R, Torre P, Antonello RM, et al: Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms: a randomized, controlled, open 14-month study. Eur Neurol 2003; 49:13-19 [MA]
46. Swartz JR, Miller BL, Lesser IM, et al: Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors. J Clin Psychiatry 1997; 58:212-216
47. Mendez MF, Shapira JS, Miller BL: Stereotypical movements and frontotemporal dementia. Mov Disord 2005; 20:742-745
48. Ishikawa H, Shimomura T, Shimizu T: [Stereotyped behaviors and compulsive complaints of pain improved by fluvoxamine in two cases of frontotemporal dementia.] Seishin Shinkeigaku Zasshi 2006; 108:1029-1035 (Japanese)
49. Huey ED, Putnam KT, Grafman J: A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. Neurology 2006; 66:17-22
50. Ikeda M, Shigenobu K, Fukuhara R, et al: Efficacy of fluvoxamine as a treatment for behavioral symptoms in frontotemporal lobar degeneration patients. Dement Geriatr Cogn Disord 2004; 17:117-121 [MA]
51. Deakin JB, Rahman S, Nestor PJ, et al: Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial. Psychopharmacology 2003; 172:400-408 [MA]
52. Lebert F, Stekke W, Hasenbroekx C, et al: Frontotemporal dementia: a randomized, controlled trial with trazodone. Dement Geriatr Cogn Disord 2004; 17:355-359 [MA]
53. Lebert F, Pasquier F: Trazodone in the treatment of behavior in frontotemporal dementia. Hum Psychopharmacol 1999; 14: 279-281 [MA]
54. Sparks DL, Woeltz VM, Markesberry WR: Alterations in brain monoamine oxidase activity in aging, Alzheimer's disease, and Pick's disease. Arch Neurol 1991; 48:718-721
55. Adler G, Martin T, Drach LM: Pharmacological treatment of frontotemporal dementia: treatment response to the MAO-A inhibitor moclobemide. Int J Geriatr Psychiatry 2003; 18:653-655
56. Alafuzoff I, Helisalmi S, Heinonen EH, et al: Selegiline treatment and the extent of degenerative changes in brain tissue of patients with Alzheimer's disease. Eur J Clin Pharmacol 2000; 55:815-819
57. Thomas T: Monoamine oxidase-B inhibitors in the treatment of Alzheimer's disease. Neurobiol Aging 2000; 21:343-348
58. Moretti R, Torre P, Antonello RM, et al: Effects of selegiline on fronto-temporal dementia: a neuropsychological evaluation. Int J Geriatr Psychiatry 2002; 17:391-392 [MA]
59. Swanberg MM: Memantine for behavioral disturbances in frontotemporal dementia: a case series. Alzheimer Dis Assoc Disord 2007; 21:164-166
60. Fellgiebel A, Müller MJ, Hiemke C, et al: Clinical improvement in a case of frontotemporal dementia under aripiprazole treatment corresponds to partial recovery of disturbed frontal glucose metabolism. World J Biol Psychiatry 2007; 8:123-126
61. Boxer AL, Lipton AM, Womack K, et al: An open-label study of memantine treatment in 3 subtypes of frontotemporal lobar degeneration. Alzheimer Dis Assoc Disord 2009; 23:211-217
62. Curtis TC, Resch DS: Case of Pick's central lobar atrophy with apparent stabilization of cognitive decline after treatment with risperidone. J Clin Psychopharmacol 2000; 20:384-385
63. Moretti R, Torre P, Antonello RM, et al: Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer's disease and other dementias: a 24-month follow-up of 68 patients. Am J Alzheimers Dis Other Demen 2003; 18:205-214
64. Kerrsens CJ, Pijnenburg YAL: Vulnerability to neuroleptic side effects in frontotemporal dementia. Eur J Neurol 2008; 15:111-112
65. Herrmann N, Lactot KL: Atypical antipsychotics for neuropsychiatric symptoms of dementia-malignant or maligned? Drug Saf 2006; 29:833-843
66. Rahman S, Robbins TW, Hodges R, et al: Methylphenidate ("Ritalin") can ameliorate abnormal risk-taking behavior in the frontal variant of frontotemporal dementia. Neuropsychopharmacology 2006; 31:651-688
67. Peters F, Perani D, Herholz K, et al: Orbitofrontal dysfunction related to both apathy and disinhibition in frontotemporal dementia. Dement Geriatr Cogn Disord 2006; 21:373-379
68. Goforth HW, Konopka L, Primeau M, et al: Quantitative electroencephalography in frontotemporal dementia with methylphenidate response: a case study. Clin EEG Neurosci 2004; 35:108-111
69. Neumann M, Sampathu DM, Kwong JL, et al: Ubiquinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006; 314:130-133
70. Goldman JS, Farmer JM, Johnson JK, et al: Comparison of healthy histories in FTLD subtypes and related tauopathies. Neurology 2005; 65:1817-1819
71. Morita M, Al-Chalabi A, Andersen PM, et al: A locus on chromosome 9p confers susceptibility to ALS and frontotemporal dementia. Neurology 2006; 66:839-844
72. Vance C, Al-Chalabi A, Ruddy D, et al: Familial amyotrophic lateral sclerosis with frontotemporal dementia is linked to a locus on chromosome 9p13.2-21.3. Brain 2006; 129:868-876
73. Baker M, Mackenzie IR, Pickering-Brown SM, et al: Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 2006; 442:916-919
74. Cruts M, Gijselinck I, van der Zee J, et al: Null mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17q21. Nature 2006; 442:920-924
75. Ahmed Z, Mackenzie IR, Hutton ML, et al: Progranulin in frontotemporal lobar degeneration and neuroinflammation. J Neuroinflammation 2007; 4:7
76. Neary D, Snowden J, Mann D: Frontotemporal dementia. Lancet Neurol 2005; 4:771-780
77. Foster NL, Wilhelmsen K, Sima AA, et al: Frontotemporal dementia and parkinsonism linked to chromosome 17: a consensus conference. Ann Neurol 1997; 41:706-715
78. Josephs KA, Petersen RC, Knopman DS, et al: Clinicopathic analysis of frontotemporal and corticobasal degenerations and PSP. Neurology 2006; 66:41-48
79. Rosso SM, Donker Kaat L, Baks T, et al: Frontotemporal dementia in the Netherlands: patient characteristics and prevalence estimates from a population-based study. Brain 2003; 126:2016-2022
80. McKhann GM, Albert MS, Grossman M, et al: Clinical and pathological diagnosis of frontotemporal dementia: report of the work group on frontotemporal dementia and Pick's disease. Arch Neurol 2001; 58:1803-1809
81. Khlistunova I, Biernat J, Wang Y, et al: Inducible expression of tau repeat domain in cell models of tauopathy: aggregation is toxic to cells but can be reversed by inhibitor drugs. J Biol Chem 2006; 281:1205-1214
82. Götz J, Ittner LM, Schonrock N: Alzheimer's disease and frontotemporal dementia: prospects of a tailored therapy? Med J Aust 2006; 185:381-384
83. Wischik C, Bentham P, Wischik D, et al: Tau aggregation inhibitor (TAI) therapy with rember (MTC) arrests disease progression in mild and moderate Alzheimer's disease over (50) 84 weeks. ICAD 2008: Alzheimer's Association International Conference on Alzheimer's Disease: Abstract 08-A-2332-ALZ. Presented July 29, 2008
84. Asuni AA, Boutajangout A, Quartermain D, et al: Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 2007; 27:9115-9129
85. Noble W, Planel E, Zehr C, et al: Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci USA 2005; 102: 6990-6995
86. Zhang B, Maiti A, Shively S, et al: Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proc Natl Acad Sci USA 2005; 102:227-231
87. Piguet O, Brooks WS, Halliday GM, et al: Similar early clinical presentations in familial and non-familial frontotemporal dementia. J Neurol Neurosurg Psychiatry 2004; 75:1743-1745
88. Hodges JR, Davies R, Xuereb J, et al: Survival in frontotemporal dementia. Neurology 2003; 61:349-354
89. Broe M, Hodges JR, Schofield E, et al: Staging disease severity in pathologically confirmed cases of frontotemporal dementia. Neurology 2003; 60:1005-1011
90. Frith U, Frith CD: Development and neurophysiology of mentalizing. Phil Trans R Soc Lond B: 2003; 358:459-473
91. D'Argembeau A, Ruby P, Collette F, et al: Distinct regions of the medial prefrontal cortex are associated with self-referential processing and perspective taking. J Cogn Neuroscience 2007; 19:935-944
92. Stuss DT, Gallup GG, Alexander MP: The frontal lobes are necessary for "theory of mind." Brain 2001; 124:279-286
93. Wedderburn C, Wear H, Brown J, et al: The utility of the Cambridge Behavioral Inventory in neurodegenerative disease. J Neurol Neurosurg Psychiatry 2008; 79:500-503
94. Blair M, Kertesz A, Davis-Faroque N, et al: Behavioral measures in frontotemporal lobar dementia and other dementias: the utility of the Frontal Behavioral Inventory and the Neuropsychiatric Inventory in a national cohort study. Dement Geriatr Cogn Disord 2007; 23:406-415
95. Milan G, Lamenza F, Iavarone A, et al: Frontal Behavioral Inventory in the differential diagnosis of dementia. Acta Neurol Scand 2008; 117:260-265
96. Kertesz A, Davidson W, McCabe P, et al: Behavioral quantitation is more sensitive than cognitive testing in frontotemporal dementia. Alzheimer Dis Assoc Disord 2003; 17:223-239
97. Salmon E, Garaux G, Delbeuck X, et al: Predominant ventromedial frontopolar metabolic impairment in frontotemporal dementia. Neuroimage 2003; 20:435-440
98. Snowden JS, Neary D, Mann DMA: Frontotemporal Lobar Degeneration: Frontotemporal Dementia, Progressive Aphasia, Semantic Dementia. London, Churchill Livingstone, 1996
99. Freedman M: Frontotemporal dementia: recommendations for therapeutic studies, designs, and approaches. Canadian Journal of Neurology 2007; 34(suppl 1):S18-24